Home > Boards > US Listed > Biotechs >

Algernon Pharmaceuticals Inc. (AGNPF)

AGNPF RSS Feed
Add AGNPF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, eqinvestor, medchem, NamesJeb
Search This Board: 
Last Post: 3/6/2021 12:56:20 AM - Followers: 200 - Board type: Free - Posts Today: 2

Algernon Pharmaceuticals is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).

 
The Algernon drug development program was the brainchild of Dr. Mark Williams, the Company’s CSO, whose innovative approach to drug discovery was developed over many years as senior scientist in the drug development industry. The company and its business model is highly capital efficient and strives to deliver maximum shareholder value.
 
Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.


Drug Repurposing Strategy

A Drug Repurposing Strategy Can Save up to 8 years of Pre-Clinical Research And Multi Millions in R&D Costs.

 The Algernon business model is to take safe approved genericized drugs, screen them in globally accepted animal models for new diseases, file new intellectual property rights and then efficiently move them into off label phase II trials in the country where they were originally approved. Once a signal is established in a human trial, the company will begin to advance the repurposed drug through a US FDA registration.

11 drug candidates were initially screened by the Company in globally accepted in vivo animal models for 4 new disease areas:

Non-alcoholic Steatohepatitis (NASH)
Chronic Kidney Disease (“CKD”)
Inflammatory Bowel Disease (IBD)
Idiopathic Pulmonary Fibrosis(IPF)

Initial studies showed that a number of the 11 drug candidates either performed equal to or better than the positive controls in each of the animal studies. Subsequent in vivo studies have confirmed their efficacy.

All Algernon research studies were conducted by 3rd party contract research organizations. The studies were well designed with proper positive controls, using the currently accepted gold standard for treatment in the disease being screened.



Targeted Diseases

Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).
 
Non–alcoholic Steatohepatitis

 

CKD

Chronic Kidney Disease

 

IBD

Inflammatory Bowel Disease

 

IPF

Idiopathic Pulmonary Fibrosis

 
Ifenprodil: The Specialized Drug Treating Coronavirus
 

Christopher J. Moreau, Chief Executive Officer
Mark Williams PhD MBA, Chief Science Officer

General Inquiriesinfo@algernonpharmaceuticals.com
Head Office: Suite 915 – 700 West Pender Street Vancouver, BC, Canada V6C 1G
Shares Outstanding:
135,732,455
  Fully Diluted: 190.0M+


  
algernonpharmaceuticals.com

 

COVID-19 UPDATE:

Algernon Pharmaceuticals receives ok from South Korea for phase two study of Ifenprodil
 
 
AGNPF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AGNPF News: Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol 02/11/2021 08:00:00 AM
PostSubject
#13563  Sticky Note Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment NamesJeb 02/11/21 03:23:15 PM
#13352  Sticky Note $AGNPF Receives Green Light from DSMB to Conduct shell3 01/19/21 08:58:35 AM
#12569  Sticky Note Check this article! medchem 12/05/20 11:43:02 AM
#14029   The Key: Timely recruitment/enrollment of patients Money $hot 03/06/21 12:56:20 AM
#14028   Let’s make lots of money? smoki 03/06/21 12:41:17 AM
#14027   Christopher Bryan, PhD Money $hot 03/05/21 10:33:09 PM
#14026   166,945,269 Issued and outstanding after new Private Placement shell3 03/05/21 10:12:13 PM
#14025   Outstanding: 155,726,729 for March 5, 2021 Report shell3 03/05/21 10:07:14 PM
#14024   Check your e-mail. News PP Closed. smoki 03/05/21 08:13:53 PM
#14023   Wise Words 4 The Weekend Warriors Money $hot 03/05/21 05:28:34 PM
#14022   Just having human data is going to make Kevausha 03/05/21 01:29:26 PM
#14021   Testing policies probably effect the number of known tcm55 03/05/21 12:54:21 PM
#14020   this is what happens when your independent data rsizzle 03/05/21 12:32:34 PM
#14019   Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b GVX808 03/05/21 12:27:07 PM
#14018   I think the distance that AGN has from rsizzle 03/05/21 11:55:52 AM
#14017   I was expecting clarification today as well. Moreau Skydive21 03/05/21 11:39:50 AM
#14016   Shell. Your numbers are very helpful. Keep on posting. Skydive21 03/05/21 11:32:02 AM
#14015   given the amount of speculation / confusion over rsizzle 03/05/21 11:22:27 AM
#14014   Tru Dat. Money $hot 03/05/21 11:20:43 AM
#14013   Whatever shell I’ve been following you for 5 Kevausha 03/05/21 11:06:46 AM
#14012   You know I can’t leave that as it’s shell3 03/05/21 10:55:58 AM
#14011   Just my opinion; shell3 is part of the Kevausha 03/05/21 10:48:54 AM
#14010   197,763,377 Total Diluted as of January 29, 2021 shell3 03/05/21 10:41:47 AM
#14009   not bad to have local news in Miami Jgregsr 03/05/21 08:06:39 AM
#14008   minor correction: Money $hot 03/05/21 07:17:29 AM
#14007   Yeah I hare your point. Money $hot 03/04/21 11:13:43 PM
#14006   Trump had everything thrown at him during his smoki 03/04/21 10:05:23 PM
#14005   There's due diligence and there's diligence that's due. Money $hot 03/04/21 09:48:08 PM
#14004   Entitled to an opinion. IF Infenprodil was saving smoki 03/04/21 09:46:51 PM
#14003   Dude, of course AP has not gained the Money $hot 03/04/21 09:35:48 PM
#14002   Infenprodil was never mentioned on Local/world news during smoki 03/04/21 08:54:51 PM
#14001   Real World Time Lines for COVID-19 Treatments from Money $hot 03/04/21 08:31:52 PM
#14000   Jgregsr, ??? Not sure how you got Grey Ghost 001 03/04/21 08:09:22 PM
#13999   how can they load up, after news.. Jgregsr 03/04/21 04:23:25 PM
#13998   Yes, and sometimes I feel like this msg GVX808 03/04/21 03:45:04 PM
#13997   Lol ... simple minds smoki 03/04/21 03:09:06 PM
#13996   There is NO guessing game going on. GVX808 03/04/21 02:53:54 PM
#13995   Soooo why the guessing game by Algernon they smoki 03/04/21 02:47:29 PM
#13994   I'm hoping that due to the fact it GVX808 03/04/21 02:36:36 PM
#13993   Soooo what is shortly after... 6 weeks my guess. smoki 03/04/21 02:15:29 PM
#13992   Words spoken by a true OG up n Money $hot 03/04/21 02:14:45 PM
#13991   Ok, I'm pretty sure you asked this question GVX808 03/04/21 01:35:14 PM
#13990   As our good friend Shell3 would say... Trader's trading Lowersioux5 03/04/21 12:46:57 PM
#13989   Shut the goddam door tomorrow ... then what lol smoki 03/04/21 10:25:51 AM
#13988   Damn, this is being slammed & driven down Grey Ghost 001 03/04/21 09:42:41 AM
#13987   Touché, Dr. Yost walked away like the Tiger Money $hot 03/03/21 11:51:42 PM
#13986   Bonjour Monsieur Money $hot Dr E 03/03/21 11:46:11 PM
#13985   Lol.. What happens after March 5th.. No guidance smoki 03/03/21 10:50:22 PM
#13984   Was reading through the FDA's guidance on developing rsizzle 03/03/21 10:35:15 PM
#13983   First Take Money $hot 03/03/21 07:51:03 PM
#13982   I am liking the fact that CM got GVX808 03/03/21 05:48:29 PM
#13981   Yes! But sadly... We're still stuck as Archie (Medchem) Lowersioux5 03/03/21 03:31:06 PM
#13980   https://www.who.int/director-general/speeches/detail/who-director-general-s-at-t Kevausha 03/03/21 03:11:16 PM
PostSubject
Consent Preferences